$XRTX

XORTX Therapeutics (NASDAQ:XRTX) shares rose 22.16% in after-hours trading after announcing plans to file a Clinical Trial Application for its gout drug candidate, XORLO, with Health Canada. The company expects this to accelerate data collection for a future FDA New Drug Application. XORTX also reported increased interest from potential commercialization partners. The stock has a market cap of $3.35M and traded between $1.59 and $7.05 over the past year.

IM Cannabis (IMCC) surged 245% with no clear catalyst, trading between $2.97 and $8.65. XORTX (XRTX) rose 12% on plans for a 2026 FDA application. Silo Pharma (SILO) gained 6.73% after a U.S. patent allowance. Biofrontera (BFRI) increased 5.65% despite no new news, following an FDA approval for Ameluz.

XORTX Therapeutics (XRTX) shares rose 12% after announcing plans to submit an Investigational New Drug application to the FDA in Q4 2026. The stock traded at $1.8997, up from $1.99, with a 52-week range of $1.59 to $7.05.

XORTX Therapeutics plans to submit an Investigational New Drug application to the FDA in Q4 2026 for its gout treatment XRx-026. The company aims to file a New Drug Application in 2027, targeting a $700M+ U.S. market. The submission follows positive clinical trial results and FDA discussions.

XORTX Therapeutics (NASDAQ: XRTX) has begun manufacturing GMP drug substance and commercial-scale tablets for its XORLO™ gout treatment. This supports the planned XRX-OXY-102 clinical study and future FDA marketing approval. The company aims to address unmet needs in gout treatment with its proprietary oxypurinol formulation.

XORTX Therapeutics Inc. (NASDAQ: XRTX, TSXV: XRTX) said director Anthony Giovinazzo will resign from its board for personal reasons. The company thanked him for his multi-year role as board chairman and work on key committees. XORTX also reiterated its late-stage gout and kidney disease drug development pipeline.

XORTX Therapeutics Inc. (NASDAQ: XRTX, TSXV: XRTX) said it appointed Depesh Narotam as an independent director effective July 27, 2026. He will sit on the Compensation, Governance and Nominating Committee. The company also outlined its late-stage pipeline for gout and kidney disease, including XRx-026, XRx-008, and XRx-101.

XORTX Therapeutics Inc. (NASDAQ: XRTX; TSXV: XRTX) said it has elected to voluntarily delist its common shares from the TSX Venture Exchange. The company cited costs and administrative burden from maintaining a dual listing and differences in regulatory environments. It expects no shareholder action; Canadian shareholders will still trade on Nasdaq.

XORTX Therapeutics has priced a public offering of 2,659,574 common shares or pre-funded warrants at US$1.88 per share, aiming to raise US$5 million in gross proceeds. The offering is expected to close around May 15, 2026, subject to regulatory approvals. Following this announcement, XRTX's stock experienced a significant negative market reaction, declining by 23.20%.

XORTX Therapeutics Inc. filed an EFFECT Form with the SEC, which became effective on May 13, 2026. This filing, with accession number 0001104659-26-057834, is a POS AM submission indicating a post-effective amendment. The company, trading under NASDAQ: XRTX, has a market cap of $3.76 million and is involved in biotechnology.